Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Limited ( (AU:FRE) ) has shared an announcement.
Firebrick Pharma Limited has appointed Rick Legleiter as a non-executive director, effective 1 August 2025. Rick brings extensive experience from senior roles in global healthcare corporations and was previously CEO at Adherium Limited. His expertise in global commercial expansion and strategic planning is expected to support Firebrick’s ongoing global expansion, particularly in the commercialization of Nasodine and other products. This appointment highlights Firebrick’s commitment to innovation and its strategic focus on expanding its market presence and shareholder value.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has launched Nasodine Nasal Spray (0.5% PVP-I) in several international markets, including the United States, Singapore, Fiji, and the South Pacific, with plans to expand into the Philippines.
Average Trading Volume: 74,631
Technical Sentiment Signal: Buy
Learn more about FRE stock on TipRanks’ Stock Analysis page.